Literature DB >> 14662108

Role of selective cholesterol absorption inhibition in the management of dyslipidemia.

Christie M Ballantyne1.   

Abstract

Ezetimibe, a cholesterol absorption inhibitor, lowered low-density lipoprotein cholesterol levels and improved high-density lipoprotein cholesterol and triglyceride levels when used as monotherapy or when coadministered with a statin in clinical trials, and its safety profile is similar to placebo or statin plus placebo. Addition of ezetimibe to ongoing statin therapy increased the proportion of patients reaching recommended low-density lipoprotein cholesterol treatment goals. Ezetimibe is an effective treatment option that may enable more patients with hypercholesterolemia to achieve optimal cholesterol levels and reduce their risk for coronary heart disease.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14662108     DOI： 10.1007/s11883-004-0116-4

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


  26 in total

1.  Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters.

Authors:  K E Berge; H Tian; G A Graf; L Yu; N V Grishin; J Schultz; P Kwiterovich; B Shan; R Barnes; H H Hobbs
Journal:  Science       Date:  2000-12-01       Impact factor: 47.728

2.  Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects.

Authors:  James E Patrick; Teddy Kosoglou; Kathe L Stauber; Kevin B Alton; Stephen E Maxwell; Yali Zhu; Paul Statkevich; Robert Iannucci; Swapan Chowdhury; Melton Affrime; Mitchell N Cayen
Journal:  Drug Metab Dispos       Date:  2002-04       Impact factor: 3.922

3.  Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption.

Authors:  M H Lee; K Lu; S Hazard; H Yu; S Shulenin; H Hidaka; H Kojima; R Allikmets; N Sakuma; R Pegoraro; A K Srivastava; G Salen; M Dean; S B Patel
Journal:  Nat Genet       Date:  2001-01       Impact factor: 38.330

4.  Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function.

Authors:  M van Heek; C Farley; D S Compton; L Hoos; H R Davis
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

5.  Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia.

Authors:  Claude Gagné; Harold E Bays; Stuart R Weiss; Pedro Mata; Katherine Quinto; Michael Melino; Meehyung Cho; Thomas A Musliner; Barry Gumbiner
Journal:  Am J Cardiol       Date:  2002-11-15       Impact factor: 2.778

6.  Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia.

Authors:  Boris Kerzner; John Corbelli; Stephan Sharp; Leslie J Lipka; Lorenzo Melani; Alexandre LeBeaut; Ramachandran Suresh; Pabak Mukhopadhyay; Enrico P Veltri
Journal:  Am J Cardiol       Date:  2003-02-15       Impact factor: 2.778

7.  The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.

Authors:  T A Pearson; I Laurora; H Chu; S Kafonek
Journal:  Arch Intern Med       Date:  2000-02-28

8.  Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia.

Authors:  R H Knopp; H Gitter; T Truitt; H Bays; C V Manion; L J Lipka; A P LeBeaut; R Suresh; B Yang; E P Veltri
Journal:  Eur Heart J       Date:  2003-04       Impact factor: 29.983

9.  In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461.

Authors:  M Van Heek; C F France; D S Compton; R L McLeod; N P Yumibe; K B Alton; E J Sybertz; H R Davis
Journal:  J Pharmacol Exp Ther       Date:  1997-10       Impact factor: 4.030

10.  Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia.

Authors:  H H Knapp; H Schrott; P Ma; R Knopp; B Chin; J M Gaziano; J M Donovan; S K Burke; M H Davidson
Journal:  Am J Med       Date:  2001-04-01       Impact factor: 4.965
View more
  1 in total

1.  Ezetimibe: its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic Fatty liver disease.

Authors:  Ornella de Bari; Brent A Neuschwander-Tetri; Min Liu; Piero Portincasa; David Q-H Wang
Journal:  J Lipids       Date:  2011-11-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.